An interventional study of A-EMDR and Treatment as Usual (TAU) in Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 83rd largest by planned enrollment of the 113 interventional ones that give a count, is one of 16 that started in 2026, is one of 83 with no phase, reaches primary completion later than 21 of the 41 other live ones, and was the 111th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–65
COMPASS Pathways · Sites in Canada, United States
Ages 18+
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 19+ · Women only
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 22 · Phase 3 8 · Phase 4 2
First in 2007; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 54 across the 113 interventional studies, 303 across the 14 observational. Of the 65 that completed or were terminated, 6 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 127 have an industry lead sponsor. The 10 most frequent:
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
Centre for Addiction and Mental Health has 7 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Stress Disorders, Post-Traumatic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137845Université de SherbrookeVirtual Reality and Cranial Nerve Non-invasive Neuromodulation to Improve Quality of Life for Veterans | 2026-12 |
| NCT07309302Université du Québec a MontréalPsychosocial Factors and Efficacy of Remote Cognitive Remediation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT07146633Centre for Addiction and Mental HealthEfficacy of an EMDR App for PTSD and SUD | 2027-01-30 |
| NCT06044675RemedyMDMA-Assisted CBCT for PTSD vs CBCT RCT | 2027-03-31 |
| NCT06335043London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sPersonalized Pharmacotherapy Using Pharmacogenetics in Veterans | 2027-04-25 |
Add all 7 to your calendar (.ics) → With an account.
Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current proposal is aimed to confirm the efficacy of this novel therapeutic method (autonomous eye movement desensitization and reprocessing; A-EMDR) in a patient group (PTSD and SUD), and to assess the feasibility of the application within this group. While there is no basis to assume lower efficacy of the treatment with this population, confirming that hypothesis is an important and helpful step before a full-performance research study can be initiated. Furthermore, this study proposal will provide additional information regarding the feasibility for this population, which will allow for a more tailored approach in future study.
This is an open-label pilot randomized, wait-list controlled trial evaluating A-EMDR for the treatment of PTSD in patients with SUD for four weeks with a follow up at week eight. Primary outcomes will be measured at the end of the study (week 4) for both groups and at follow up (week 8) for the A-EMDR group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: A-EMDR
Other: Treatment as Usual (TAU)
Participants in the treatment group will receive Autonomous Eye movement desensitization and reprocessing (A-EMDR) therapy delivered through an app on their device. Participants will be asked to complete 3 sessions per week for 4 consecutive weeks. During the treatment period, participants will also attend clinical sessions which will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol.
Participants are advised to continue seeking mental health care as usual and will be added to a waitlist for A-EMDR. They will also attend two clinical sessions. Sessions may last 15 to 60 minutes and will focus on factors such as the therapeutic alliance, assessing the participant's current state, reviewing recent alcohol and drug use, reviewing PTSD symptoms, providing a brief counseling intervention, enhancing positive expectancies, inspiring hope, and encouraging adherence to the study protocol. Participants will continue to receive any usual healthcare services as per local standard of care. TAU and other medical appointments will be checked for attendance throughout the study period.
Changes in PTSD symptoms and alcohol/drug consumption during 4 weeks of treatment.
We will monitor changes in PTSD symptoms using the clinician-administered PTSD Scale DSM-5 (CAPS-5)/PTSD checklist for DSM-5 (PCL-5) from baseline to weeks four and eight. We will monitor overall alcohol and drug consumption and cravings using the TLFB and CEQ, respectively, over the eight weeks period. In line with previous studies, we will use the Brief Coping Orientation to Problems Experienced (COPE) and subjective measures of substance use coping questionnaire (i.e., How many times have you used a problematic substance for trauma-related problems in the last week? 1) to evaluate the exact frequency of substance used for coping with trauma-related problems from baseline to weeks four and eight. The change in these outcomes will be compared between the A-EMDR and TAU groups.
Time frame: From enrollment to the end of treatment at 4 weeks
The feasibility and engagement of A-EMDR during 4 weeks of treatment.
We will assess the feasibility and engagement of A-EMDR by evaluating the rate of retention (number of participants enrolled after deemed eligible, number of sessions completed for each participant, number of participants who withdraw and/or lost-to-follow-up after enrollment in the study) in the group over the four-week treatment period. We will assess acceptability using quantitative scales to determine their satisfaction with the treatment at weeks four and eight.
Time frame: From enrollment to the end of the treatment at 4 weeks
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 12 months is below that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
Centre for Addiction and Mental Health →